NASDAQ:TNDM

Tandem Diabetes Care (TNDM) Stock Forecast, Price & News

$21.24

-1.53 (-6.72%)

(As of 09/21/2023 ET)

Compare

Today's Range: $21.13
▼
$22.47
50-Day Range: $21.24
▼
$36.22
52-Week Range: $21.01
▼
$58.82

Volume: 801,150 shs
Average Volume: 1.37 million shs
Market Capitalization: $1.38 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $46.80

Tandem Diabetes Care MarketRank™ Forecast

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 120.3% Upside
$46.80 Price Target
Short Interest: Healthy
11.34% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.64
Upright™ Environmental Score
News Sentiment: 1.21
Based on 10 Articles This Week
Insider Trading: Acquiring Shares
$21,450 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.49) to ($1.15) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.68 out of 5 stars

Medical Sector

102nd out of 965 stocks

Surgical & Medical Instruments Industry

15th out of 96 stocks

4.2

Analyst's Opinion

Consensus Rating
Tandem Diabetes Care has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 5 buy ratings, 6 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $46.80, Tandem Diabetes Care has a forecasted upside of 120.3% from its current price of $21.24.
Amount of Analyst Coverage
Tandem Diabetes Care has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
11.34% of the outstanding shares of Tandem Diabetes Care have been sold short.
Short Interest Ratio / Days to Cover
Tandem Diabetes Care has a short interest ratio ("days to cover") of 5.3.
Change versus previous month
Short interest in Tandem Diabetes Care has recently decreased by 11.30%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Tandem Diabetes Care does not currently pay a dividend.
Dividend Growth
Tandem Diabetes Care does not have a long track record of dividend growth.

4.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Tandem Diabetes Care has received a 80.42% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Insulin pumps" product. See details.
Environmental Sustainability
The Environmental Impact score for Tandem Diabetes Care is -0.64.

3.4

News and Social Media Coverage

News Sentiment
Tandem Diabetes Care has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Tandem Diabetes Care this week, compared to 4 articles on an average week.
Search Interest
Only 11 people have searched for TNDM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
3 people have added Tandem Diabetes Care to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tandem Diabetes Care insiders have bought more of their company's stock than they have sold. Specifically, they have bought $21,450.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 2.50% of the stock of Tandem Diabetes Care is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Tandem Diabetes Care are expected to grow in the coming year, from ($1.49) to ($1.15) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tandem Diabetes Care is -6.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tandem Diabetes Care is -6.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Tandem Diabetes Care has a P/B Ratio of 3.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Tandem Diabetes Care (NASDAQ:TNDM) Stock

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

TNDM Price History

30 days | 90 days | 365 days | Advanced Chart

TNDM Stock News Headlines

September 21, 2023 | benzinga.com

TNDM Shareholder Alert: Investors with Large Losses Should Contact Robbins LLP for Information About Recovery Against Tandem Diabetes Care, Inc.

September 19, 2023 | businesswire.com

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Tandem Diabetes Care, Inc. (TNDM) Investors

September 22, 2023 | Chaikin Analytics (Ad)

This is the #1 Stock to Buy for the AI Tidal Wave

Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.

September 18, 2023 | technews.tmcnet.com

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Tandem Diabetes Care, Inc. (TNDM) Investors

September 15, 2023 | tmcnet.com

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Tandem Diabetes Care, Inc. (TNDM) on Behalf of Investors

September 15, 2023 | benzinga.com

Tandem Diabetes Care, Inc. (TNDM) Investor Alert: Robbins LLP Reminds Investors of Class Action Filed Against Tandem Diabetes Care, Inc.

September 15, 2023 | finance.yahoo.com

Unraveling the Future of Tandem Diabetes Care Inc (TNDM): A Deep Dive into Key Metrics

September 15, 2023 | businesswire.com

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Tandem Diabetes Care, Inc. (TNDM) on Behalf of Investors

September 22, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

September 14, 2023 | businesswire.com

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Tandem Diabetes Care, Inc. (TNDM) on Behalf of Investors

September 14, 2023 | americanbankingnews.com

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Average Rating of "Hold" by Brokerages

September 13, 2023 | benzinga.com

The Law Offices of Frank R. Cruz Announces Investigation of Tandem Diabetes Care, Inc. (TNDM) on Behalf of Investors

September 13, 2023 | stockhouse.com

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Tandem Diabetes Care, Inc. with Losses of $100,000 to Contact the Firm

September 13, 2023 | benzinga.com

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Tandem Diabetes Care, Inc. (TNDM)

September 13, 2023 | businesswire.com

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Tandem Diabetes Care, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – TNDM

September 11, 2023 | technews.tmcnet.com

Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Tandem Diabetes Care, Inc.

September 8, 2023 | cnbc.com

Obesity drugs’ popularity put a dent in these stocks. Why analysts say they’re still worth buying

September 7, 2023 | msn.com

Insulet, Tandem Diabetes drop as weight loss drugs impact insulin use

September 7, 2023 | finance.yahoo.com

Is Tandem Diabetes Care (TNDM) Too Good to Be True? A Comprehensive Analysis of a Potential ...

September 7, 2023 | finance.yahoo.com

Is Tandem Diabetes Care Inc (TNDM) Set to Underperform? Analyzing the Factors Limiting Growth

August 22, 2023 | msn.com

Citigroup Maintains Tandem Diabetes Care (TNDM) Neutral Recommendation

August 21, 2023 | markets.businessinsider.com

What 9 Analyst Ratings Have To Say About Tandem Diabetes Care

August 17, 2023 | finance.yahoo.com

A Bull Market Is Coming: 2 Beaten-Down Stocks to Buy and Hold

August 13, 2023 | finance.yahoo.com

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Analysts Just Slashed This Year's Estimates

August 8, 2023 | msn.com

Barclays Maintains Tandem Diabetes Care (TNDM) Overweight Recommendation

August 6, 2023 | markets.businessinsider.com

Barclays Remains a Buy on Tandem Diabetes Care (TNDM)

August 5, 2023 | msn.com

TD Cowen Maintains Tandem Diabetes Care (TNDM) Outperform Recommendation

See More Headlines

Receive TNDM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter.

TNDM Company Calendar

Last Earnings: 8/03/2023
Today: 9/21/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TNDM
CUSIP: N/A
CIK: 1438133
Web: www.tandemdiabetes.com
Phone: (858) 366-6900
Fax: N/A
Employees: 2,600
Year Founded: 2006

Price Target and Rating

Average Stock Price Forecast: $46.80
High Stock Price Forecast: $75.00
Low Stock Price Forecast: $30.00
Forecasted Upside/Downside: +120.3%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.48)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-94,590,000.00
Net Margins: -28.40%
Pretax Margin: -28.05%
Return on Equity: -20.29%
Return on Assets: -7.76%

Debt

Debt-to-Equity Ratio: 0.86
Current Ratio: 4.38
Quick Ratio: 3.53

Sales & Book Value

Annual Sales: $790.35 million
Price / Sales: 1.75
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.84 per share
Price / Book: 3.11

Miscellaneous

Outstanding Shares: 65,078,000
Free Float: 63,451,000
Market Cap: $1.38 billion
Optionable: Optionable
Beta: 0.87

Social Links

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. John F. Sheridan (Age 68)
Pres, CEO & Director
Comp: $1.23M

Ms. Leigh A. Vosseller (Age 50)
Exec. VP, CFO & Treasurer
Comp: $665.43k

Mr. David B. Berger Esq. (Age 53)
Exec. VP & COO
Comp: $670.18k

Ms. Susan M. Morrison (Age 44)
Exec. VP & Chief Admin. Officer
Comp: $674.76k

Mr. Brian B. Hansen (Age 55)
Exec. VP & Chief Commercial Officer
Comp: $650.19k

Ms. Elizabeth Anne Gasser (Age 46)
Exec. VP & Chief Strategy Officer
Comp: $606.83k

Mr. Rick A. Carpenter (Age 60)
Chief Technical Officer

Ms. Shannon M. Hansen (Age 57)
Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.

Mr. Ross Sylvia
VP of Marketing

Mr. Tom Fox
Sr. VP of HR & Organizational Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TNDM Stock - Frequently Asked Questions

Should I buy or sell Tandem Diabetes Care stock right now?: 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TNDM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TNDM, but not buy additional shares or sell existing shares.
View TNDM analyst ratings or view top-rated stocks.
What is Tandem Diabetes Care's stock price forecast for 2023?: 12 Wall Street research analysts have issued 12-month price objectives for Tandem Diabetes Care's stock. Their TNDM share price forecasts range from $30.00 to $75.00. On average, they predict the company's stock price to reach $46.80 in the next year. This suggests a possible upside of 120.3% from the stock's current price.
View analysts price targets for TNDM or view top-rated stocks among Wall Street analysts.
How have TNDM shares performed in 2023?: Tandem Diabetes Care's stock was trading at $44.95 on January 1st, 2023. Since then, TNDM shares have decreased by 52.7% and is now trading at $21.24.
View the best growth stocks for 2023 here.
When is Tandem Diabetes Care's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our TNDM earnings forecast.
How were Tandem Diabetes Care's earnings last quarter?: Tandem Diabetes Care, Inc. (NASDAQ:TNDM) issued its quarterly earnings results on Thursday, August, 3rd. The medical device company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.24. The medical device company earned $195.92 million during the quarter, compared to analysts' expectations of $201.62 million. Tandem Diabetes Care had a negative net margin of 28.40% and a negative trailing twelve-month return on equity of 20.29%.
What ETFs hold Tandem Diabetes Care's stock?: ETFs with the largest weight of Tandem Diabetes Care (NASDAQ:TNDM) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Fidelity Digital Health ETF (FDHT), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Equipment ETF (XHE), Harbor Corporate Culture Small Cap ETF (HAPS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and Syntax Stratified SmallCap ETF (SSLY).iShares U.S. Medical Devices ETF (IHI).
When did Tandem Diabetes Care's stock split?: Shares of Tandem Diabetes Care reverse split on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What guidance has Tandem Diabetes Care issued on next quarter's earnings?: Tandem Diabetes Care updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $785.00M-, compared to the consensus revenue estimate of $881.47 million.

What is John Sheridan's approval rating as Tandem Diabetes Care's CEO?: 11 employees have rated Tandem Diabetes Care Chief Executive Officer John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among the company's employees.
What other stocks do shareholders of Tandem Diabetes Care own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Block (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).
What is Tandem Diabetes Care's stock symbol?: Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."
Who are Tandem Diabetes Care's major shareholders?: Tandem Diabetes Care's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.78%), Capital World Investors (9.97%), State Street Corp (3.47%), Bellevue Group AG (3.22%), Champlain Investment Partners LLC (2.49%) and Brown Capital Management LLC (2.45%). Insiders that own company stock include Brian B Hansen, Brian B Hansen, Christopher J Twomey, Christopher J Twomey, David B Berger, Dick Allen, Elizabeth Anne Gasser, James Leal, John F Sheridan, Kathleen Mcgroddy-Goetz, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson, Rebecca B Robertson and Susan Morrison.
View institutional ownership trends.
How do I buy shares of Tandem Diabetes Care?: Shares of TNDM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Tandem Diabetes Care's stock price today?: One share of TNDM stock can currently be purchased for approximately $21.24.
How much money does Tandem Diabetes Care make?: Tandem Diabetes Care (NASDAQ:TNDM) has a market capitalization of $1.38 billion and generates $790.35 million in revenue each year. The medical device company earns $-94,590,000.00 in net income (profit) each year or ($3.48) on an earnings per share basis.
How many employees does Tandem Diabetes Care have?: The company employs 2,600 workers across the globe.
How can I contact Tandem Diabetes Care?: Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The official website for the company is www.tandemdiabetes.com. The medical device company can be reached via phone at (858) 366-6900 or via email at smorrison@tandemdiabetes.com.

This page (NASDAQ:TNDM) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial